View More Recent Stories
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $85 at RBC Capital
-
BMO Capital Reiterates BioMarin (BMRN) at Outperform: unique opportunity to buy the dip and can attract M&A interest
-
Barclays Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharma (BMRN) Weakness Tied to Data From Ascendis Pharma (ASND)
-
Canaccord Genuity Reiterates Hold Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Increasing unusual call option volume: SMMT TERN SATS BNTX BRZE FRPT FLUT APLD TECS BMRN
-
BMO Capital Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
TD Cowen Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $122 at Piper Sandler
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $95 at Scotiabank
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $118 at Truist Securities
-
BioMarin Pharma (BMRN) Provides New Corporate Strategy, Introduces 2027 Financial Guidance
-
BioMarin Pharma (BMRN) Enters $600M Revolving Credit Facility
-
BioMarin Pharma (BMRN) Halted, News Pending
-
BioMarin Pharma (BMRN) to reduce its global workforce by approximately 225 employees
-
Bernstein SocGen Group Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Goldman Sachs Shares 2 Idiosyncratic Trade Ideas off NVIDIA (NVDA) Earnings, Buy Calls on Dollar General (DG) and BioMarin Pharma (BMRN)
-
Piper Sandler Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharma (BMRN) Announces New R&D and Business Development Leadership
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $115 at Stifel
-
Bernstein SocGen Group Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
-
Eight defensive growth stocks to own right now
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $120 at TD Cowen
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $112 at Stifel
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $115 at Evercore ISI
-
BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
-
BioMarin Pharma (BMRN) Announces Updated Strategy for ROCTAVIAN to Focus on U.S., Germany and Italy
-
Piper Sandler Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Citi Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
CrowdSrike, KKR, and GoDaddy shares rise after S&P 500 inclusion news

